Daraxonrasib, an experimental drug by Revolution Medicines, nearly doubled median survival for pancreatic cancer patients in a late-stage trial presented at ASCO 2026.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.